We found that MGMT methylation status was a poor predictor, but both IDH and FREM2 PAL2 was effective as the GBM PFS biomarkers, and this was confirmed for FREM2 PAL2 in an independent experimental validation study (Figure 5). Here, FREM2 is linked to glioblastoma.